Shasun and Debiopharm to commercialise Huperzine-A
Shasun Pharmaceuticals and Debiopharm Group have entered into a licensing agreement to manufacture and commercialise the acetylcholinesterase inhibitor “Huperzine-A” (HupA) that has been shown to improve cognitive performance in patients that suffer from Alzheimer?s Disease (AD). According to the deal, Shasun Pharmaceuticals…